SUPERNUS PHARMACEUTICALS, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- SUPERNUS PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2026-06-30 was 80.90K shares, a 0.41% increase year-over-year.
- SUPERNUS PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2026-03-31 was 443.35K shares, a 365.79% increase year-over-year.
- SUPERNUS PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2025-12-31 was 261.53K shares, a 41.17% decline year-over-year.
- SUPERNUS PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2025-09-30 was 996.21K shares.
- SUPERNUS PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2025 was 1.43M shares, a 83.44% increase from fiscal 2024.
- SUPERNUS PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2024 was 781.44K shares, a 202.70% increase from fiscal 2023.
- SUPERNUS PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2023 was 258.15K shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 12 month |
|---|---|---|
| 2026-06-30 | 80.90K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-03 | 1.78M shares derived: sum of 4 quarters · filed 2026-08-03 |
| 2026-03-31 | 443.35K shares 10-Q · filed 2026-05-05 | 1.78M shares derived: sum of 4 quarters · filed 2026-05-05 |
| 2025-12-31 | 261.53K shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | 1.43M shares 10-K · filed 2026-03-02 |
| 2025-09-30 | 996.21K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | 1.62M shares derived: sum of 4 quarters · filed 2026-03-02 |
| 2025-06-30 | 80.57K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-05 | |
| 2025-03-31 | 95.18K shares 10-Q · filed 2025-05-06 | |
| 2024-12-31 | 444.57K shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | 781.44K shares 10-K · filed 2026-03-02 |
| 2023-12-31 | 258.15K shares 10-K · filed 2025-02-25 | |
| 2013-06-30 | 40.51M shares 10-Q · filed 2013-08-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |